Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NAV-240 in Healthy Volunteers
NCT06181786Phase 1Completed
- Sponsor
- Navigator Medicines
- Start
- Nov 2023
- Primary completion
- Sep 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing NAV-240 SAD with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events. Started Nov 2023; status: completed.
02
Drugs
NAV-240
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06181786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06181786.